Translated from our German original by AI. The German text was researched, written, and edited by the Psychedelia Foundation team and remains the authoritative version.
São Paulo / Basel, 28 May 2026. In a recent publication in the journal Frontiers in Neuroscience, physicians report an unusual observation. A woman over the age of 80, who was in a far advanced stage of Alzheimer’s disease, unexpectedly regained parts of her mental and physical abilities after a single dose of psilocybin-containing mushrooms. The improvement lasted for several weeks. The scientists involved warn emphatically against overstated hopes. This is an observation in a single patient, they note, and must under no circumstances be read as general proof of efficacy, let alone as a cure.
At the time of the observation, the Japanese-American patient looked back on a ten-year history of illness. In the five years before the treatment she had required nursing care and had become almost entirely silent, usually able to make herself understood only in single syllables or words. She also had persistent urinary incontinence, could barely walk without help, had difficulty swallowing and showed hardly any emotional response to her surroundings.
In a medically supervised, purely observational trial at a private practice, the woman took a high dose of five grams of dried mushrooms of the Psilocybe cubensis strain “Enigma”. Her body reacted strongly immediately after ingestion. She began to sweat heavily, developed a palpable fever and fell into a very deep, sleep-like state. About 19 hours after the start of the trial, the unexpected happened: the patient woke up and talked fluently and entirely spontaneously about her past for several hours.
In the days that followed, the recovery extended to many other areas of daily life. The patient recognized her family again, was noticeably more attentive and held eye contact. To everyone’s surprise she could suddenly walk again without any help, dressed herself at times and showed genuine humor and an emotional smile. What the physicians found particularly remarkable was that the incontinence of many years disappeared completely and the patient stayed dry day and night for weeks.
One month after the first trial, a second session was carried out with a somewhat lower dose of three grams. Here too the woman was very talkative, described happy inner images, such as surfing with her son on a peaceful island, and moved noticeably more nimbly and lightly when walking.
Despite these fascinating experiences, the researchers temper high expectations in the fight against memory loss. The report’s evidentiary value is severely limited. Because this is a pure observation in a single person, there is no comparison with a control group that would have received a placebo. In addition, the woman’s Alzheimer’s disease was diagnosed ten years ago purely on the basis of outward symptoms. As modern brain scans and laboratory tests were missing, other conditions, such as impaired blood flow in the brain, cannot be ruled out as contributing factors.
There is therefore no firm proof that psilocybin was really responsible for the improvement; in theory, natural fluctuation in the course of the illness could also explain it. The researchers suspect a kind of biological reset behind the phenomenon. The compound could have briefly shaken up and reordered the remaining neural networks in the brain, which are normally blocked at this late stage. The study does not prove that Alzheimer’s is reversible. What it does show is that even in a severely damaged brain, hidden reserves may still lie dormant and can be reawakened for a short time under very particular conditions. The report is intended as an impulse to examine this undiscovered potential more closely in large, controlled studies.
